CMTM4 Promotes the Motility of Colon Cancer Cells Under Radiation and is Associated with an Unfavorable Neoadjuvant Chemoradiotherapy Response and Patient Survival in Rectal Cancer

Overview

Journal Oncol Lett

Date 2025 Jan 22

PMID 39839608

Authors

Lujing Yang

Zhiting Miao

Ningning Li

Lin Meng

Qin Feng

Dongbo Qiao

Ping Wang

Yue Wang

Yanhua Bai

Zhongwu Li

Shenyi Lian

Affiliations

Soon will be listed here.

Abstract

Neoadjuvant chemoradiotherapy (nCRT) is the standard treatment for locally advanced rectal cancer (LARC). Pathological complete regression is closely linked to disease outcomes. However, biomarkers predicting nCRT response and patient survival are lacking for LARC. In the present study, the clinical characteristics and follow-up information of 228 patients with LARC were retrospectively collected. Immunohistochemistry (IHC), reverse transcription-quantitative PCR (RT-qPCR), Kaplan-Meier and multivariate analyses were used to evaluate the expression and predict the role of CKLF-like MARVEL transmembrane domain member 4 (CMTM4) in LARC. Additionally, lentiviral short hairpin (sh)RNA was used to interfere with CMTM4 expression. The phenotype of CMTM4-knockdown LoVo cells was determined by colony formation, migration and invasion assays under irradiation (IR) treatment. RNA-sequencing (RNA-seq) analysis was also used to explore the CMTM4-regulated genes in LoVo-shCMTM4 cells compared with control cells. RT-qPCR was then used to confirm the expression of these CMTM4-regulated genes. CMTM4 expression in pre-nCRT tissues indicated an unfavorable response and a short disease-free survival (DFS) with LARC. The expression of CMTM4 significantly increased following nCRT treatment. Additionally, CMTM4 knockdown increased the proliferation, migration and invasion of colon cancer cells; however, IR disrupted the cell migration and invasion induced by CMTM4 knockdown. RNA-seq analysis, the Tumor Immune Estimation Resource database and RT-qPCR indicated that CMTM4 was involved in different signaling pathways and regulated immune-related genes such as cluster of differentiation 66b, chemokine (CXC motif) ligand 8 (CXCL8) and programmed cell death 1. Furthermore, CXCL8 expression was found to be negatively associated with CMTM4 expression in patients with LARC by IHC and RT-qPCR. CXCL8 expression on invasion margin regions in post-operative tissues was also an inferior predictor of DFS in patients with LARC. In conclusion, CMTM4 may predict the nCRT response and outcomes in patients with LARC.

References

Wang L, Li Z, Li Z, Li Y, Sun Y, Ji J . Efficacy and safety of neoadjuvant intensity-modulated radiotherapy with concurrent capecitabine for locally advanced rectal cancer. Dis Colon Rectum. 2015; 58(2):186-92. DOI: 10.1097/DCR.0000000000000294. View

Zhang S, Wang L, Li Y, Wang G, Li L, Sun S . MicroRNA-126 Attenuates the Effect of Chemokine CXCL8 on Proliferation, Migration, Apoptosis, and MAPK-Dependent Signaling Activity of Vascular Endothelial Cells Cultured in a Medium with High Glucose Concentration. Bull Exp Biol Med. 2021; 171(2):202-207. DOI: 10.1007/s10517-021-05195-3. View

Shin J, Huh J, Lee W, Yun S, Kim H, Cho Y . Clinical prediction model of pathological response following neoadjuvant chemoradiotherapy for rectal cancer. Sci Rep. 2022; 12(1):7145. PMC: 9065005. DOI: 10.1038/s41598-022-10974-7. View

Hu X, Yuan L, Ma T . Mechanisms of JAK-STAT signaling pathway mediated by CXCL8 gene silencing on epithelial-mesenchymal transition of human cutaneous melanoma cells. Oncol Lett. 2020; 20(2):1973-1981. PMC: 7377181. DOI: 10.3892/ol.2020.11706. View

Principe S, Zapater-Latorre E, Arribas L, Garcia-Miragall E, Bagan J . Salivary IL-8 as a putative predictive biomarker of radiotherapy response in head and neck cancer patients. Clin Oral Investig. 2021; 26(1):437-448. PMC: 8791883. DOI: 10.1007/s00784-021-04017-0. View

Shen Y, Zhang B, Wei X, Guan X, Zhang W . CXCL8 is a prognostic biomarker and correlated with TNBC brain metastasis and immune infiltration. Int Immunopharmacol. 2021; 103:108454. DOI: 10.1016/j.intimp.2021.108454. View

Leon X, Garcia J, Farre N, Majercakova K, Aviles-Jurado F, Quer M . Predictive capacity of IL-8 expression in head and neck squamous carcinoma patients treated with radiotherapy or chemoradiotherapy. Acta Otorrinolaringol Esp (Engl Ed). 2021; 72(6):337-343. DOI: 10.1016/j.otoeng.2020.05.006. View

Martin S, Heneghan H, Winter D . Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg. 2012; 99(7):918-28. DOI: 10.1002/bjs.8702. View

Zhou H, Li J, Liu L, Lou J, Ren Z . Increased CMTM4 mRNA expression predicts a poor prognosis in patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2020; 19(6):596-601. DOI: 10.1016/j.hbpd.2020.06.004. View

10.

Zhu X, Zhang S, Tan S, Li D, Chen X, Kong J . Expression of CMTM4 shows clinical significance in lung cancer. Transl Cancer Res. 2022; 9(10):6214-6220. PMC: 8798101. DOI: 10.21037/tcr-20-1254. View

11.

Chui N, Cheu J, Yuen V, Chiu D, Goh C, Lee D . Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cell-Mediated Antitumor Immunity Through PD-L1. Hepatol Commun. 2021; 6(1):178-193. PMC: 8710793. DOI: 10.1002/hep4.1682. View

12.

Bhangu A, Fitzgerald J, Slesser A, Northover J, Faiz O, Tekkis P . Prognostic significance of extramural vascular invasion in T4 rectal cancer. Colorectal Dis. 2013; 15(11):e665-71. DOI: 10.1111/codi.12421. View

13.

David J, Dominguez C, Hamilton D, Palena C . The IL-8/IL-8R Axis: A Double Agent in Tumor Immune Resistance. Vaccines (Basel). 2016; 4(3). PMC: 5041016. DOI: 10.3390/vaccines4030022. View

14.

Zhang T, Yu H, Dai X, Zhang X . CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment. Front Immunol. 2022; 13:971428. PMC: 9359082. DOI: 10.3389/fimmu.2022.971428. View

15.

Liu S, Yang S, Yu H, Luo H, Chen G, Gao Y . A nomogram for predicting 10-year cancer specific survival in patients with pathological T3N0M0 rectal cancer. Front Med (Lausanne). 2022; 9:977652. PMC: 9441689. DOI: 10.3389/fmed.2022.977652. View

16.

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu J . TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017; 77(21):e108-e110. PMC: 6042652. DOI: 10.1158/0008-5472.CAN-17-0307. View

17.

Yi M, Peng C, Xia B, Gan L . CXCL8 Facilitates the Survival and Paclitaxel-Resistance of Triple-Negative Breast Cancers. Clin Breast Cancer. 2021; 22(2):e191-e198. DOI: 10.1016/j.clbc.2021.06.009. View

18.

Meng Z, Zhang L, Cai X, Wang X, She F, Chen Y . IL-8 is a novel prometastatic chemokine in intrahepatic cholangiocarcinoma that induces CXCR2-PI3K/AKT signaling upon CD97 activation. Sci Rep. 2023; 13(1):18711. PMC: 10618468. DOI: 10.1038/s41598-023-45496-3. View

19.

Matos L, Trufelli D, de Matos M, da Silva Pinhal M . Immunohistochemistry as an important tool in biomarkers detection and clinical practice. Biomark Insights. 2010; 5:9-20. PMC: 2832341. DOI: 10.4137/bmi.s2185. View

20.

Dekker E, Tanis P, Vleugels J, Kasi P, Wallace M . Colorectal cancer. Lancet. 2019; 394(10207):1467-1480. DOI: 10.1016/S0140-6736(19)32319-0. View